Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction

Heart failure (HF) is a common cause of cardiovascular mortality and morbidity. Despite advances in treatment, the prognosis remains poor. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors decrease HF events by 27–39% in high-risk patients with type 2 diabetes mellitus (T2DM). Moreover, the DAPA-H...

Descripción completa

Detalles Bibliográficos
Autores principales: Elserafy, Ahmed S., Reda, Ashraf, Farag, Elsayed, Mostafa, Tamer, Farag, Nabil, Elbahry, Atef, Sanad, Osama, Bendary, Ahmed, Elkersh, Ahmed, Attia, Ihab, Selim, Mohammed, Khamis, Hazem, Issak, Emad R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626381/
https://www.ncbi.nlm.nih.gov/pubmed/34780022
http://dx.doi.org/10.1007/s40261-021-01095-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626381/
https://www.ncbi.nlm.nih.gov/pubmed/34780022
http://dx.doi.org/10.1007/s40261-021-01095-6

Ejemplares similares